---
title: "WuXi Biologics (Cayman) Inc. (WXXWY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/WXXWY.US.md"
symbol: "WXXWY.US"
name: "WuXi Biologics (Cayman) Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T15:31:09.056Z"
locales:
  - [en](https://longbridge.com/en/quote/WXXWY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/WXXWY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/WXXWY.US.md)
---

# WuXi Biologics (Cayman) Inc. (WXXWY.US)

## Company Overview

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.wuxibiologics.com](https://www.wuxibiologics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.31)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 5 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.74% |  |
| Net Profit YoY | 47.59% |  |
| P/B Ratio | 2.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17333216703.40 |  |
| Revenue | 3054196947.65 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.02% | B |
| Profit Margin | 22.53% | A |
| Gross Margin | 45.98% | B |
| Revenue YoY | 17.74% | B |
| Net Profit YoY | 47.59% | B |
| Total Assets YoY | 16.64% | B |
| Net Assets YoY | 21.68% | A |
| Cash Flow Margin | 129.19% | B |
| OCF YoY | 17.74% | B |
| Turnover | 0.36 | C |
| Gearing Ratio | 16.73% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - WuXi Biologics (Cayman) Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.74%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "47.59%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "17333216703.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3054196947.65",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.02%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "22.53%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "45.98%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "17.74%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "47.59%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "16.64%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "21.68%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "129.19%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "17.74%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.36",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.73%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 25.19 | 10/59 | 34.74 | 30.39 | 27.50 |
| PB | 2.57 | 28/59 | 3.13 | 2.79 | 2.55 |
| PS (TTM) | 5.68 | 43/59 | 7.04 | 6.21 | 5.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/WXXWY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/WXXWY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/WXXWY.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**